{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:03:15Z","timestamp":1780452195243,"version":"3.54.1"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_215043"],"award-info":[{"award-number":["310030_215043"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lassa fever, a viral hemorrhagic fever caused by the arenavirus Lassa virus (LASV), affects thousands of individuals annually, highlighting the need for a vaccine. Yet, immunological correlates of viral load control remain poorly defined. Here we study vaccination-induced immunity in a surrogate LASV challenge model in mice. We find that LASV-cross-reactive B cell immunity induced by the glycoprotein of distantly related arenaviruses, such as lymphocytic choriomeningitis virus (LCMV), provides significant viral load control. Counter to common concepts, suppression of viremia is observed in the absence of CD8 T cells or neutralizing antibodies but correlates with non-neutralizing glycoprotein-specific antibody responses. Adoptive cell transfer experiments with monoclonal LCMV-specific B cells demonstrates that these cells suppress viral loads when previously activated by a heterologous cross-reactive glycoprotein and diversified by somatic hypermutation. These findings establish vaccination-induced B cell immunity to the LASV glycoprotein as a correlate of viral load control, independently of virus-neutralizing antibody titers at the time of challenge.<\/jats:p>","DOI":"10.1038\/s41467-026-71472-2","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:17:23Z","timestamp":1775477843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["B cell immunity to the Lassa virus glycoprotein is a correlate of vaccination-induced virus control in mice"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-4734","authenticated-orcid":false,"given":"Tiago","family":"Abreu-Mota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Friederike","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9840-8074","authenticated-orcid":false,"given":"Dorothee","family":"Winterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tintignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Fixemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brodmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemre","family":"Seven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1674-6839","authenticated-orcid":false,"given":"Claudia","family":"Reichmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3726-3306","authenticated-orcid":false,"given":"Anna Lena","family":"Kastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weldy V.","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela","family":"Dimitrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2708-2507","authenticated-orcid":false,"given":"Gert","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1594-3189","authenticated-orcid":false,"given":"Daniel D.","family":"Pinschewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"71472_CR1","doi-asserted-by":"publisher","first-page":"7079","DOI":"10.1128\/JVI.00526-15","volume":"89","author":"C Huang","year":"2015","unstructured":"Huang, C. et al. Highly Pathogenic New World and Old World Human Arenaviruses Induce Distinct Interferon Responses in Human Cells. J Virol 89, 7079\u20137088 (2015).","journal-title":"J Virol"},{"key":"71472_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/infdis\/155.3.437","volume":"155","author":"JB McCormick","year":"1987","unstructured":"McCormick, J. B., Webb, P. A., Krebs, J. W., Johnson, K. M. & Smith, E. S. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155, 437\u2013444 (1987).","journal-title":"J Infect Dis"},{"key":"71472_CR3","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1038\/s41591-024-03232-y","volume":"30","author":"DRM Smith","year":"2024","unstructured":"Smith, D. R. M. et al. Health and economic impacts of Lassa vaccination campaigns in West Africa. Nat Med 30, 3568\u20133577 (2024).","journal-title":"Nat Med"},{"key":"71472_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijid.2020.08.021","volume":"100","author":"SC Ficenec","year":"2020","unstructured":"Ficenec, S. C. et al. Lassa Fever Induced Hearing Loss: The Neglected Disability of Hemorrhagic Fever. Int J Infect Dis 100, 82\u201387 (2020).","journal-title":"Int J Infect Dis"},{"key":"71472_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/inthealth\/ihac076","volume":"15","author":"D Simons","year":"2023","unstructured":"Simons, D. Lassa fever cases suffer from severe underreporting based on reported fatalities. Int Health 15, 608\u2013610 (2023).","journal-title":"Int Health"},{"key":"71472_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/tmi.13876","volume":"28","author":"G Sulis","year":"2023","unstructured":"Sulis, G., Peebles, A. & Basta, N. E. Lassa fever vaccine candidates: A scoping review of vaccine clinical trials. Trop Med Int Health 28, 420\u2013431 (2023).","journal-title":"Trop Med Int Health"},{"key":"71472_CR7","unstructured":"https:\/\/clinicaltrials.gov. NCT04794218 (US CTR);PACTR202108781239363; NCT04055454 (US CTR); NCT03805984 (US CTR); NCT06546709."},{"key":"71472_CR8","doi-asserted-by":"publisher","unstructured":"Ibukun, F. I. Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development. Viruses 12 (2020). https:\/\/doi.org\/10.3390\/v12040386","DOI":"10.3390\/v12040386"},{"key":"71472_CR9","doi-asserted-by":"publisher","first-page":"102827","DOI":"10.1016\/j.tmaid.2025.102827","volume":"64","author":"E Ortiz-Prado","year":"2025","unstructured":"Ortiz-Prado, E. et al. Hemorrhagic fevers caused by South American Mammarenaviruses: A comprehensive review of epidemiological and environmental factors related to potential emergence. Travel Med Infect Dis 64, 102827 (2025).","journal-title":"Travel Med Infect Dis"},{"key":"71472_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1086\/514211","volume":"177","author":"JI Maiztegui","year":"1998","unstructured":"Maiztegui, J. I. et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 177, 277\u2013283 (1998).","journal-title":"AHF Study Group. J Infect Dis"},{"key":"71472_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(84)90299-X","volume":"2","author":"DA Enria","year":"1984","unstructured":"Enria, D. A., Briggiler, A. M., Fernandez, N. J., Levis, S. C. & Maiztegui, J. I. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 2, 255\u2013256 (1984).","journal-title":"Lancet"},{"key":"71472_CR12","doi-asserted-by":"publisher","first-page":"114708","DOI":"10.1016\/j.celrep.2024.114708","volume":"43","author":"PJM Brouwer","year":"2024","unstructured":"Brouwer, P. J. M. et al. Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses. Cell Rep 43, 114708 (2024).","journal-title":"Cell Rep"},{"key":"71472_CR13","first-page":"421","volume":"52","author":"J Casals","year":"1975","unstructured":"Casals, J., Buckley, S. M. & Cedeno, R. Antigenic properties of the arenaviruses. Bulletin of the World Health Organization 52, 421\u2013427 (1975).","journal-title":"Bulletin of the World Health Organization"},{"key":"71472_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/0035-9203(85)90388-8","volume":"79","author":"PB Jahrling","year":"1985","unstructured":"Jahrling, P. B., Frame, J. D., Rhoderick, J. B. & Monson, M. H. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg 79, 380\u2013384 (1985).","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"71472_CR15","doi-asserted-by":"publisher","first-page":"e1005276","DOI":"10.1371\/journal.ppat.1005276","volume":"11","author":"R Sommerstein","year":"2015","unstructured":"Sommerstein, R. et al. Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathog 11, e1005276 (2015).","journal-title":"PLoS Pathog"},{"key":"71472_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12985-024-02585-7","volume":"21","author":"BM Warner","year":"2024","unstructured":"Warner, B. M., Safronetz, D. & Stein, D. R. Current perspectives on vaccines and therapeutics for Lassa Fever. Virol J 21, 320 (2024).","journal-title":"Virol J"},{"key":"71472_CR17","doi-asserted-by":"publisher","first-page":"105673","DOI":"10.1016\/j.ebiom.2025.105673","volume":"114","author":"AS Enriquez","year":"2025","unstructured":"Enriquez, A. S. et al. Mapping the antibody response to Lassa virus vaccination of non-human primates. EBioMedicine 114, 105673 (2025).","journal-title":"EBioMedicine"},{"key":"71472_CR18","doi-asserted-by":"publisher","first-page":"105647","DOI":"10.1016\/j.ebiom.2025.105647","volume":"114","author":"CL Cooper","year":"2025","unstructured":"Cooper, C. L. et al. Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials. EBioMedicine 114, 105647 (2025).","journal-title":"EBioMedicine"},{"key":"71472_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06741-w","volume":"9","author":"T Abreu-Mota","year":"2018","unstructured":"Abreu-Mota, T. et al. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nat Commun 9, 4223 (2018).","journal-title":"Nat Commun"},{"key":"71472_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41376-6","volume":"14","author":"AJ Ronk","year":"2023","unstructured":"Ronk, A. J. et al. A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection. Nat Commun 14, 5603 (2023).","journal-title":"Nat Commun"},{"key":"71472_CR21","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.chom.2022.10.018","volume":"30","author":"PJM Brouwer","year":"2022","unstructured":"Brouwer, P. J. M. et al. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection. Cell Host Microbe 30, 1759\u20131772 e1712 (2022).","journal-title":"Cell Host Microbe"},{"key":"71472_CR22","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","volume":"2","author":"TW Geisbert","year":"2005","unstructured":"Geisbert, T. W. et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2, e183 (2005).","journal-title":"PLoS Med"},{"key":"71472_CR23","doi-asserted-by":"publisher","unstructured":"Mateo, M. et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci Transl Med 13 (2021). https:\/\/doi.org\/10.1126\/scitranslmed.abf6348","DOI":"10.1126\/scitranslmed.abf6348"},{"key":"71472_CR24","doi-asserted-by":"publisher","unstructured":"Carnec, X. et al. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. J Virol 92 (2018). https:\/\/doi.org\/10.1128\/JVI.02230-17","DOI":"10.1128\/JVI.02230-17"},{"key":"71472_CR25","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1128\/JVI.74.15.6777-6783.2000","volume":"74","author":"SP Fisher-Hoch","year":"2000","unstructured":"Fisher-Hoch, S. P., Hutwagner, L., Brown, B. & McCormick, J. B. Effective vaccine for lassa fever. J Virol 74, 6777\u20136783 (2000).","journal-title":"J Virol"},{"key":"71472_CR26","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1128\/JVI.01948-08","volume":"83","author":"S Baize","year":"2009","unstructured":"Baize, S. et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol 83, 5890\u20135903 (2009).","journal-title":"J Virol"},{"key":"71472_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s42003-020-01543-7","volume":"4","author":"N Baillet","year":"2021","unstructured":"Baillet, N. et al. Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques. Commun Biol 4, 27 (2021).","journal-title":"Commun Biol"},{"key":"71472_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2016.138","volume":"17","author":"JB Prescott","year":"2017","unstructured":"Prescott, J. B. et al. Immunobiology of Ebola and Lassa virus infections. Nat Rev Immunol 17, 195\u2013207 (2017).","journal-title":"Nat Rev Immunol"},{"key":"71472_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1128\/iai.44.2.528-533.1984","volume":"44","author":"PB Jahrling","year":"1984","unstructured":"Jahrling, P. B. & Peters, C. J. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 44, 528\u2013533 (1984).","journal-title":"Infect Immun"},{"key":"71472_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0035-9203(84)90107-X","volume":"78","author":"JD Frame","year":"1984","unstructured":"Frame, J. D., Verbrugge, G. P., Gill, R. G. & Pinneo, L. The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg 78, 319\u2013324 (1984).","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"71472_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11544","volume":"7","author":"JE Robinson","year":"2016","unstructured":"Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun 7, 11544 (2016).","journal-title":"Nat Commun"},{"key":"71472_CR32","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.immuni.2024.06.013","volume":"57","author":"CR Carr","year":"2024","unstructured":"Carr, C. R. et al. Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex. Immunity 57, 2061\u20132076 e2011 (2024).","journal-title":"Immunity"},{"key":"71472_CR33","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2019.07.020","volume":"178","author":"KM Hastie","year":"2019","unstructured":"Hastie, K. M. et al. Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization. Cell 178, 1004\u20131015 e1014 (2019).","journal-title":"Cell"},{"key":"71472_CR34","doi-asserted-by":"publisher","first-page":"e2304876120","DOI":"10.1073\/pnas.2304876120","volume":"120","author":"RW Cross","year":"2023","unstructured":"Cross, R. W. et al. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus. Proc Natl Acad Sci USA 120, e2304876120 (2023).","journal-title":"Proc Natl Acad Sci USA"},{"key":"71472_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coviro.2019.07.003","volume":"37","author":"RW Cross","year":"2019","unstructured":"Cross, R. W. et al. Antibody therapy for Lassa fever. Curr Opin Virol 37, 97\u2013104 (2019).","journal-title":"Curr Opin Virol"},{"key":"71472_CR36","doi-asserted-by":"publisher","first-page":"eabq0991","DOI":"10.1126\/scitranslmed.abq0991","volume":"14","author":"H Li","year":"2022","unstructured":"Li, H. et al. A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus. Sci Transl Med 14, eabq0991 (2022).","journal-title":"Sci Transl Med"},{"key":"71472_CR37","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm.4396","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med 23, 1146\u20131149 (2017).","journal-title":"Nat Med"},{"key":"71472_CR38","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1473-3099(20)30737-4","volume":"21","author":"J Strampe","year":"2021","unstructured":"Strampe, J. et al. Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study. Lancet Infect Dis 21, 876\u2013886 (2021).","journal-title":"Lancet Infect Dis"},{"key":"71472_CR39","doi-asserted-by":"publisher","first-page":"ofae575","DOI":"10.1093\/ofid\/ofae575","volume":"11","author":"E Ogbaini-Emovon","year":"2024","unstructured":"Ogbaini-Emovon, E. et al. Virus Load Kinetics in Lassa Fever Patients Treated With Ribavirin: A Retrospective Cohort Study From Southern Nigeria. Open Forum Infect Dis 11, ofae575 (2024).","journal-title":"Open Forum Infect Dis"},{"key":"71472_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/jpids\/piae083","volume":"13","author":"A Duvignaud","year":"2024","unstructured":"Duvignaud, A. et al. Presentation and Outcomes of Lassa Fever in Children in Nigeria: A Prospective Cohort Study (LASCOPE). J Pediatric Infect Dis Soc 13, 513\u2013522 (2024).","journal-title":"J Pediatric Infect Dis Soc"},{"key":"71472_CR41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/infdis\/155.3.456","volume":"155","author":"KM Johnson","year":"1987","unstructured":"Johnson, K. M. et al. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155, 456\u2013464 (1987).","journal-title":"J Infect Dis"},{"key":"71472_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00006454-200101000-00013","volume":"20","author":"SA Plotkin","year":"2001","unstructured":"Plotkin, S. A. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 20, 63\u201375 (2001).","journal-title":"Pediatr Infect Dis J"},{"key":"71472_CR43","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1128\/CVI.00230-14","volume":"21","author":"JL Excler","year":"2014","unstructured":"Excler, J. L., Ake, J., Robb, M. L., Kim, J. H. & Plotkin, S. A. Nonneutralizing functional antibodies: a new \u201cold\u201d paradigm for HIV vaccines. Clin Vaccine Immunol 21, 1023\u20131036 (2014).","journal-title":"Clin Vaccine Immunol"},{"key":"71472_CR44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1517\/14712598.2012.743527","volume":"13","author":"HL Robinson","year":"2013","unstructured":"Robinson, H. L. Non-neutralizing antibodies in prevention of HIV infection. Expert Opin Biol Ther 13, 197\u2013207 (2013).","journal-title":"Expert Opin Biol Ther"},{"key":"71472_CR45","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","volume":"287","author":"JA Wilson","year":"2000","unstructured":"Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664\u20131666 (2000).","journal-title":"Science"},{"key":"71472_CR46","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.4049\/jimmunol.181.6.4168","volume":"181","author":"DM Carragher","year":"2008","unstructured":"Carragher, D. M., Kaminski, D. A., Moquin, A., Hartson, L. & Randall, T. D. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181, 4168\u20134176 (2008).","journal-title":"J Immunol"},{"key":"71472_CR47","doi-asserted-by":"publisher","first-page":"e1003207","DOI":"10.1371\/journal.ppat.1003207","volume":"9","author":"BJ Laidlaw","year":"2013","unstructured":"Laidlaw, B. J. et al. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog 9, e1003207 (2013).","journal-title":"PLoS Pathog"},{"key":"71472_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","volume":"239","author":"B Moss","year":"2011","unstructured":"Moss, B. Smallpox vaccines: targets of protective immunity. Immunol Rev 239, 8\u201326 (2011).","journal-title":"Immunol Rev"},{"key":"71472_CR49","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/eji.201343566","volume":"43","author":"K Richter","year":"2013","unstructured":"Richter, K. & Oxenius, A. Non-neutralizing antibodies protect from chronic LCMV infection independently of activating FcgammaR or complement. Eur J Immunol 43, 2349\u20132360 (2013).","journal-title":"Eur J Immunol"},{"key":"71472_CR50","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/eji.201343565","volume":"43","author":"T Straub","year":"2013","unstructured":"Straub, T. et al. Nucleoprotein-specific nonneutralizing antibodies speed up LCMV elimination independently of complement and FcgammaR. Eur J Immunol 43, 2338\u20132348 (2013).","journal-title":"Eur J Immunol"},{"key":"71472_CR51","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1084\/jem.20051557","volume":"203","author":"L Hangartner","year":"2006","unstructured":"Hangartner, L. et al. Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. J Exp Med 203, 2033\u20132042 (2006). jem.20051557 [pii].","journal-title":"J Exp Med"},{"key":"71472_CR52","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/eji.202049068","volume":"51","author":"D Stoycheva","year":"2021","unstructured":"Stoycheva, D. et al. Non-neutralizing antibodies protect against chronic LCMV infection by promoting infection of inflammatory monocytes in mice. Eur J Immunol 51, 1423\u20131435 (2021).","journal-title":"Eur J Immunol"},{"key":"71472_CR53","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/infdis\/146.3.360","volume":"146","author":"DH Walker","year":"1982","unstructured":"Walker, D. H. et al. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J Infect Dis 146, 360\u2013368 (1982).","journal-title":"J Infect Dis"},{"key":"71472_CR54","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF02122441","volume":"175","author":"PB Jahrling","year":"1986","unstructured":"Jahrling, P. B. & Peters, C. J. Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development. Med Microbiol Immunol 175, 165\u2013167 (1986).","journal-title":"Med Microbiol Immunol"},{"key":"71472_CR55","first-page":"5","volume":"134","author":"CJ Peters","year":"1987","unstructured":"Peters, C. J. et al. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 134, 5\u201368 (1987).","journal-title":"Curr Top Microbiol Immunol"},{"key":"71472_CR56","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0042-6822(83)90135-6","volume":"130","author":"M Bruns","year":"1983","unstructured":"Bruns, M., Cihak, J., Muller, G. & Lehmann-Grube, F. Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization. Virology 130, 247\u2013251 (1983).","journal-title":"Virology"},{"key":"71472_CR57","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1084\/jem.187.4.649","volume":"187","author":"P Seiler","year":"1998","unstructured":"Seiler, P. et al. Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J Exp Med 187, 649\u2013654 (1998).","journal-title":"J Exp Med"},{"key":"71472_CR58","doi-asserted-by":"publisher","first-page":"8340","DOI":"10.1128\/JVI.00236-14","volume":"88","author":"R Sommerstein","year":"2014","unstructured":"Sommerstein, R. et al. Evolution of recombinant lymphocytic choriomeningitis virus\/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness. J Virol 88, 8340\u20138348 (2014).","journal-title":"J Virol"},{"key":"71472_CR59","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.virol.2013.04.010","volume":"442","author":"AM Lee","year":"2013","unstructured":"Lee, A. M., Cruite, J., Welch, M. J., Sullivan, B. & Oldstone, M. B. Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp\/LCMV chimeric virus. Virology 442, 114\u2013121 (2013).","journal-title":"Virology"},{"key":"71472_CR60","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1128\/iai.37.2.771-778.1982","volume":"37","author":"PB Jahrling","year":"1982","unstructured":"Jahrling, P. B., Smith, S., Hesse, R. A. & Rhoderick, J. B. Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun 37, 771\u2013778 (1982).","journal-title":"Infect Immun"},{"key":"71472_CR61","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/0035-9203(85)90386-4","volume":"79","author":"PB Jahrling","year":"1985","unstructured":"Jahrling, P. B., Frame, J. D., Smith, S. B. & Monson, M. H. Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. Trans R Soc Trop Med Hyg 79, 374\u2013379 (1985).","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"71472_CR62","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.4049\/jimmunol.178.4.2192","volume":"178","author":"K Kumazaki","year":"2007","unstructured":"Kumazaki, K. et al. AID\u2212\/\u2212mus\u2212\/\u2212 mice are agammaglobulinemic and fail to maintain B220-CD138+ plasma cells. J Immunol 178, 2192\u20132203 (2007).","journal-title":"J Immunol"},{"key":"71472_CR63","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.4049\/jimmunol.138.7.2278","volume":"138","author":"TP Leist","year":"1987","unstructured":"Leist, T. P., Cobbold, S. P., Waldmann, H., Aguet, M. & Zinkernagel, R. M. Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol 138, 2278\u20132281 (1987).","journal-title":"J Immunol"},{"key":"71472_CR64","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1084\/jem.174.6.1425","volume":"174","author":"WP Fung-Leung","year":"1991","unstructured":"Fung-Leung, W. P., Kundig, T. M., Zinkernagel, R. M. & Mak, T. W. Immune response against lymphocytic choriomeningitis virus infection in mice without CD8 expression. J Exp Med 174, 1425\u20131429 (1991).","journal-title":"J Exp Med"},{"key":"71472_CR65","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1128\/jvi.61.6.1867-1874.1987","volume":"61","author":"D Moskophidis","year":"1987","unstructured":"Moskophidis, D., Cobbold, S. P., Waldmann, H. & Lehmann-Grube, F. Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response. J Virol 61, 1867\u20131874 (1987).","journal-title":"J Virol"},{"key":"71472_CR66","doi-asserted-by":"publisher","first-page":"e2318657121","DOI":"10.1073\/pnas.2318657121","volume":"121","author":"M Florova","year":"2024","unstructured":"Florova, M. et al. Central tolerance shapes the neutralizing B cell repertoire against a persisting virus in its natural host. Proc Natl Acad Sci USA 121, e2318657121 (2024).","journal-title":"Proc Natl Acad Sci USA"},{"key":"71472_CR67","doi-asserted-by":"publisher","first-page":"110061","DOI":"10.1016\/j.celrep.2021.110061","volume":"37","author":"YI Ertuna","year":"2021","unstructured":"Ertuna, Y. I. et al. Vectored antibody gene delivery restores host B and T cell control of persistent viral infection. Cell Rep 37, 110061 (2021).","journal-title":"Cell Rep"},{"key":"71472_CR68","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/eji.1830180221","volume":"18","author":"P Vieira","year":"1988","unstructured":"Vieira, P. & Rajewsky, K. The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 18, 313\u2013316 (1988).","journal-title":"Eur J Immunol"},{"key":"71472_CR69","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1371\/journal.ppat.0020051","volume":"2","author":"A Bergthaler","year":"2006","unstructured":"Bergthaler, A. et al. Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog 2, e51 (2006).","journal-title":"PLoS Pathog"},{"key":"71472_CR70","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri1783","volume":"6","author":"L Hangartner","year":"2006","unstructured":"Hangartner, L., Zinkernagel, R. M. & Hengartner, H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6, 231\u2013243 (2006).","journal-title":"Nat Rev Immunol"},{"key":"71472_CR71","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/ni.1991","volume":"12","author":"M Wei","year":"2011","unstructured":"Wei, M. et al. Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat Immunol 12, 264\u2013270 (2011). ni.1991 [pii].","journal-title":"Nat Immunol"},{"key":"71472_CR72","doi-asserted-by":"publisher","unstructured":"Mateo, M. et al. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci Transl Med 11 https:\/\/doi.org\/10.1126\/scitranslmed.aaw3163 2019.","DOI":"10.1126\/scitranslmed.aaw3163"},{"key":"71472_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00930-z","volume":"9","author":"G Scher","year":"2024","unstructured":"Scher, G. et al. Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease. NPJ Vaccines 9, 143 (2024).","journal-title":"NPJ Vaccines"},{"key":"71472_CR74","doi-asserted-by":"publisher","first-page":"16027","DOI":"10.1038\/mto.2016.27","volume":"3","author":"L Evgin","year":"2016","unstructured":"Evgin, L. et al. Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Mol Ther Oncolytics 3, 16027 (2016).","journal-title":"Mol Ther Oncolytics"},{"key":"71472_CR75","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1126\/science.276.5321.2024","volume":"276","author":"MF Bachmann","year":"1997","unstructured":"Bachmann, M. F. et al. The role of antibody concentration and avidity in antiviral protection. Science 276, 2024\u20132027 (1997).","journal-title":"Science"},{"key":"71472_CR76","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010\u20131014 (2020).","journal-title":"Science"},{"key":"71472_CR77","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.celrep.2019.12.023","volume":"30","author":"B Fallet","year":"2020","unstructured":"Fallet, B. et al. Chronic Viral Infection Promotes Efficient Germinal Center B Cell Responses. Cell Rep 30, 1013\u20131026 e1017 (2020).","journal-title":"Cell Rep"},{"key":"71472_CR78","doi-asserted-by":"publisher","unstructured":"Amanat, F. et al. Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses. mSphere 3 https:\/\/doi.org\/10.1128\/mSphere.00189-18 (2018).","DOI":"10.1128\/mSphere.00189-18"},{"key":"71472_CR79","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ijid.2021.02.105","volume":"105","author":"Y Ushijima","year":"2021","unstructured":"Ushijima, Y. et al. Identification of potential novel hosts and the risk of infection with lymphocytic choriomeningitis virus in humans in Gabon, Central Africa. Int J Infect Dis 105, 452\u2013459 (2021).","journal-title":"Int J Infect Dis"},{"key":"71472_CR80","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1128\/JVI.01009-14","volume":"89","author":"N N\u2019Dilimabaka","year":"2015","unstructured":"N\u2019Dilimabaka, N. et al. Evidence of Lymphocytic Choriomeningitis Virus (LCMV) in Domestic Mice in Gabon: Risk of Emergence of LCMV Encephalitis in Central Africa. Journal of Virology 89, 1456\u20131460 (2015).","journal-title":"Journal of Virology"},{"key":"71472_CR81","doi-asserted-by":"publisher","first-page":"e1000836","DOI":"10.1371\/journal.ppat.1000836","volume":"6","author":"L Flatz","year":"2010","unstructured":"Flatz, L. et al. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog 6, e1000836 (2010).","journal-title":"PLoS Pathog"},{"key":"71472_CR82","doi-asserted-by":"publisher","first-page":"e1005656","DOI":"10.1371\/journal.ppat.1005656","volume":"12","author":"L Oestereich","year":"2016","unstructured":"Oestereich, L. et al. Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever. PLoS Pathog 12, e1005656 (2016).","journal-title":"PLoS Pathog"},{"key":"71472_CR83","doi-asserted-by":"publisher","first-page":"e1010557","DOI":"10.1371\/journal.ppat.1010557","volume":"18","author":"J Maruyama","year":"2022","unstructured":"Maruyama, J. et al. CD4 T-cell depletion prevents Lassa fever associated hearing loss in the mouse model. PLoS Pathog 18, e1010557 (2022).","journal-title":"PLoS Pathog"},{"key":"71472_CR84","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/eji.201847962","volume":"49","author":"T Straub","year":"2019","unstructured":"Straub, T. & Pircher, H. Enhancing immunity prevents virus-induced T-cell-mediated immunopathology in B cell-deficient mice. Eur J Immunol 49, 782\u2013789 (2019).","journal-title":"Eur J Immunol"},{"key":"71472_CR85","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1084\/jem.167.5.1749","volume":"167","author":"TP Leist","year":"1988","unstructured":"Leist, T. P., Ruedi, E. & Zinkernagel, R. M. Virus-triggered immune suppression in mice caused by virus-specific cytotoxic T cells. J Exp Med 167, 1749\u20131754 (1988).","journal-title":"J Exp Med"},{"key":"71472_CR86","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1084\/jem.164.4.1075","volume":"164","author":"RM Zinkernagel","year":"1986","unstructured":"Zinkernagel, R. M. et al. T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay?. J Exp Med 164, 1075\u20131092 (1986).","journal-title":"J Exp Med"},{"key":"71472_CR87","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1021\/acs.molpharmaceut.0c00270","volume":"17","author":"JM White","year":"2020","unstructured":"White, J. M. et al. Removal of Fc Glycans from [(89)Zr]Zr-DFO-Anti-CD8 Prevents Peripheral Depletion of CD8(+) T Cells. Mol Pharm 17, 2099\u20132108 (2020).","journal-title":"Mol Pharm"},{"key":"71472_CR88","doi-asserted-by":"publisher","unstructured":"Fallet, B. et al. Interferon-driven deletion of antiviral B cells at the onset of chronic infection. Sci. Immunol. 1. https:\/\/doi.org\/10.1126\/sciimmunol.aah6817","DOI":"10.1126\/sciimmunol.aah6817"},{"key":"71472_CR89","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.immuni.2024.11.021","volume":"58","author":"AL Kastner","year":"2025","unstructured":"Kastner, A. L. et al. Durable lymphocyte subset elimination upon a single dose of AAV-delivered depletion antibody dissects immune control of chronic viral infection. Immunity 58, 481\u2013498 e410 (2025).","journal-title":"Immunity"},{"key":"71472_CR90","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0092-8674(00)00078-7","volume":"102","author":"M Muramatsu","year":"2000","unstructured":"Muramatsu, M. et al. Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme. Cell 102, 553\u2013563 (2000).","journal-title":"Cell"},{"key":"71472_CR91","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.4049\/jimmunol.160.10.4776","volume":"160","author":"M Boes","year":"1998","unstructured":"Boes, M. et al. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J Immunol 160, 4776\u20134787 (1998).","journal-title":"J Immunol"},{"key":"71472_CR92","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.immuni.2017.11.023","volume":"48","author":"RK Abbott","year":"2018","unstructured":"Abbott, R. K. et al. Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. Immunity 48, 133\u2013146 e136 (2018).","journal-title":"Immunity"},{"key":"71472_CR93","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nm.2104","volume":"16","author":"Flatz","year":"2010","unstructured":"Flatz et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 16, 339\u2013345 (2010).","journal-title":"Nat Med"},{"key":"71472_CR94","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/oxfordjournals.molbev.a025808","volume":"14","author":"O Gascuel","year":"1997","unstructured":"Gascuel, O. BIONJ: an improved version of the NJ algorithm based on a simple model of sequence data. Mol Biol Evol 14, 685\u2013695 (1997).","journal-title":"Mol Biol Evol"},{"key":"71472_CR95","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1099\/vir.0.82428-0","volume":"88","author":"A Bergthaler","year":"2007","unstructured":"Bergthaler, A., Merkler, D., Horvath, E., Bestmann, L. & Pinschewer, D. D. Contributions of the lymphocytic choriomeningitis virus glycoprotein and polymerase to strain-specific differences in murine liver pathogenicity. J Gen Virol 88, 592\u2013603 (2007). 88\/2\/592 [pii].","journal-title":"J Gen Virol"},{"key":"71472_CR96","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.1073\/pnas.1332709100","volume":"100","author":"DD Pinschewer","year":"2003","unstructured":"Pinschewer, D. D., Perez, M., Sanchez, A. B. & de la Torre, J. C. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc Natl Acad Sci USA 100, 7895\u20137900 (2003).","journal-title":"Proc Natl Acad Sci USA"},{"key":"71472_CR97","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jviromet.2009.11.004","volume":"163","author":"N Ray","year":"2010","unstructured":"Ray, N., Whidby, J., Stewart, S., Hooper, J. W. & Bertolotti-Ciarlet, A. Study of Andes virus entry and neutralization using a pseudovirion system. J Virol Methods 163, 416\u2013423 (2010).","journal-title":"J Virol Methods"},{"key":"71472_CR98","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","volume":"78","author":"M Garbutt","year":"2004","unstructured":"Garbutt, M. et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78, 5458\u20135465 (2004).","journal-title":"J Virol"},{"key":"71472_CR99","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1099\/vir.0.80788-0","volume":"86","author":"A Hanika","year":"2005","unstructured":"Hanika, A. et al. Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J Gen Virol 86, 1455\u20131465 (2005).","journal-title":"J Gen Virol"},{"key":"71472_CR100","first-page":"885","volume":"22","author":"N Williams","year":"1972","unstructured":"Williams, N., Kraft, N. & Shortman, K. The separation of different cell classes from lymphoid organs. VI. The effect of osmolarity of gradient media on the density distribution of cells. Immunology 22, 885\u2013899 (1972).","journal-title":"Immunology"},{"key":"71472_CR101","doi-asserted-by":"publisher","unstructured":"Wickham, H. et al. Welcome to the Tidyverse. J. Open Source Softw. 4 https:\/\/doi.org\/10.21105\/joss.01686 (2019).","DOI":"10.21105\/joss.01686"},{"key":"71472_CR102","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41592-019-0654-x","volume":"17","author":"RA Amezquita","year":"2020","unstructured":"Amezquita, R. A. et al. Orchestrating single-cell analysis with Bioconductor. Nat Methods 17, 137\u2013145 (2020).","journal-title":"Nat Methods"},{"key":"71472_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1662-y","volume":"20","author":"ATL Lun","year":"2019","unstructured":"Lun, A. T. L. et al. EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. Genome Biol 20, 63 (2019).","journal-title":"Genome Biol"},{"key":"71472_CR104","first-page":"2122","volume":"5","author":"AT Lun","year":"2016","unstructured":"Lun, A. T., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res 5, 2122 (2016).","journal-title":"F1000Res"},{"key":"71472_CR105","doi-asserted-by":"publisher","unstructured":"Aboyoun P, G. R. pwalign: Perform pairwise sequence alignments. https:\/\/doi.org\/10.18129\/B9.bioc.pwalign, R package version 1.6.0,https:\/\/bioconductor.org\/packages\/pwalign (2025).","DOI":"10.18129\/B9.bioc.p"},{"key":"71472_CR106","doi-asserted-by":"publisher","first-page":"11650","DOI":"10.1128\/JVI.00955-07","volume":"81","author":"B Eschli","year":"2007","unstructured":"Eschli, B. et al. Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus. J Virol 81, 11650\u201311657 (2007).","journal-title":"J Virol"},{"key":"71472_CR107","doi-asserted-by":"publisher","first-page":"110303","DOI":"10.1016\/j.celrep.2022.110303","volume":"38","author":"M Sahin","year":"2022","unstructured":"Sahin, M. et al. Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors. Cell Rep 38, 110303 (2022).","journal-title":"Cell Rep"},{"key":"71472_CR108","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1128\/JVI.02240-09","volume":"84","author":"K Schlie","year":"2010","unstructured":"Schlie, K. et al. Viral protein determinants of Lassa virus entry and release from polarized epithelial cells. J Virol 84, 3178\u20133188 (2010).","journal-title":"J Virol"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71472-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71472-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71472-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:02:12Z","timestamp":1780448532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71472-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71472"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71472-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.D.P. is a founder, consultant and shareholder of Hookipa Pharma Inc. commercializing arenavirus-based vector technology, and he as well as W.V.B. are listed as inventor on corresponding patents. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4908"}}